Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like diabetes and even Ebola affecting more and more of the population, pharmaceutical companies are racing to find cures – further  advancing medicine and driving their stock prices up. Corporations like Pfizer (NYSE:PFE) and Gilead Sciences (NASDAQ:GILD) are leading the charge against disease but smaller companies such as Myland (NASDAQ:MYL) are interesting investments as well.

Recent Articles

Trade of the Day: Merck (MRK)

With major U.S. stock indexes returning to bullish trends, today's trade is a call option in "Big Pharma" stock Merck (MRK). More 

Great Biotech Stocks for Retirement Investors

Yes, Biotech stocks DO belong in your retirement portfolio. Here are three ways to add them and reap the rewards. More 

Pfizer, Merck Stock – Same Ol’ Slumping Revenues, Same Mixed Prospects

The loss of exclusivity on blockbuster drugs continued to weigh in the top line at both Pfizer and Merck in the most recent quarter. More 

Inovio Pharmaceuticals Announces 1-4 Reverse Split for INO Stock

Inovio Pharmaceuticals said that its shareholders had voted to approve a 1-for-4 reverse stock split. INO stock fell more than 5%. More 

CLVS: Clovis Oncology Lung Cancer Drug Gets Breakthrough Therapy Designation

Clovis Oncology says the Food and Drug Administration has granted Breakthrough Therapy status to its new lung cancer drug, sending CLVS shares bouncing. More 

AZN, PFE: Pfizer Confirms Interest in Buying AstraZeneca

Pfizer says it has approached AstraZeneca about a possible $100 billion merger deal, sending AZN stock surging in Monday trading. More 

2 Clear Signs That Biotechs and Pharmaceuticals Have Peaked

Pharmaceuticals and biotechs have been too hot for their own good, fueled by increasingly iffy M&A and an oddly high level of IPO activity. More 

CYTK: Cytokinetics Stock in Ugly Free Fall on ALS Drug Fail

Cytokinetics stock plunged 60% after CYTK revealed that its amyotrophic lateral sclerosis drug hadn't met the primary goal of a mid-stage clinical trial. More 

ABBV: AbbVie Beats Street on Soaring Humira Sales

Pharmaceutical-maker AbbVie posted first-quarter sales that beat estimates on surging sales of its Humira drug, sending ABBV stock higher. More 

Grass Pollen Allergy? New Grastek Pill From Merck Hits Shelves Soon

Merck says the U.S. Food and Drug Administration has approve the release of its Grastek grass pollen allergy drug, which will launch later this month. More